To summarise these results, the three-drug combination of STING agonist, with reduced doses of olaparib and AZD1775 can confer significant survival advantage in the TNBC tumour models with low level of pre-existing T cell infiltrate compared with the combination of olaparib and AZD1775. This evidence concerns the gene STING1 and neoplasm.